At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
PF-04937319 high dose +2 moredrug
Likely dose
PF-04937319 high dose 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, 3- Period, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Two Dose Levels of Pf-04937319 In Japanese Subjects With Type 2 Diabetes Mellitus as Monotherapy
In Brief
A Phase 1 clinical trial evaluating PF-04937319 high dose, PF-04937319 low dose, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartJan 2015
Primary CompletionMar 2015
TodayJul 2026
First PostedNov 17, 2014
Enrollment StartJan 1, 2015
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.6 years ago
Interventions
PF-04937319 high dosedrug
tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
PF-04937319 low dosedrug
tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
Placebodrug
tablets, breakfast plus lunch, 7 days